US Bancorp DE Buys 1,091 Shares of AVANOS MEDICAL, INC. (NYSE:AVNS)

US Bancorp DE grew its holdings in shares of AVANOS MEDICAL, INC. (NYSE:AVNS) by 7.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,184 shares of the company’s stock after acquiring an additional 1,091 shares during the quarter. US Bancorp DE’s holdings in AVANOS MEDICAL were worth $218,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its stake in shares of AVANOS MEDICAL by 27.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after acquiring an additional 644,267 shares in the last quarter. Brown Advisory Inc. raised its stake in shares of AVANOS MEDICAL by 1.4% during the first quarter. Brown Advisory Inc. now owns 1,931,163 shares of the company’s stock worth $27,674,000 after acquiring an additional 26,069 shares in the last quarter. Northern Trust Corp raised its stake in shares of AVANOS MEDICAL by 4.9% during the fourth quarter. Northern Trust Corp now owns 526,763 shares of the company’s stock worth $8,386,000 after acquiring an additional 24,720 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in shares of AVANOS MEDICAL by 43.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock worth $7,874,000 after acquiring an additional 148,902 shares in the last quarter. Finally, Clark Estates Inc. NY purchased a new position in shares of AVANOS MEDICAL during the first quarter worth approximately $7,077,000. 95.17% of the stock is owned by hedge funds and other institutional investors.

AVANOS MEDICAL Stock Up 1.9%

Shares of NYSE AVNS opened at $10.95 on Friday. The company has a quick ratio of 1.58, a current ratio of 2.64 and a debt-to-equity ratio of 0.12. AVANOS MEDICAL, INC. has a 52 week low of $9.30 and a 52 week high of $25.36. The firm’s fifty day moving average is $11.79 and its 200 day moving average is $13.26. The company has a market cap of $508.22 million, a price-to-earnings ratio of -1.09 and a beta of 1.12.

AVANOS MEDICAL (NYSE:AVNS) last issued its earnings results on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). AVANOS MEDICAL had a positive return on equity of 6.16% and a negative net margin of 66.89%. The firm had revenue of $175.00 million during the quarter, compared to analysts’ expectations of $165.50 million. During the same period in the previous year, the firm earned $0.34 earnings per share. On average, equities research analysts expect that AVANOS MEDICAL, INC. will post 1.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th.

AVANOS MEDICAL Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.